AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
“I can retire… with peace”: Nir Zuk says Palo Alto Networks finally achieved his 20-year vision with $25B CyberArk acquisition
2
Mobileye lays off 200 employees; Company's shares down more than 40% this year
3
ZIM faces pivotal vote as company weighs at least three acquisition offers
4
Nice puts Actimize up for sale at a $1.5-2 billion price tag
5
Johny Srouji weighs leaving Apple, raising stakes for the Israeli executive who built its silicon program
More news

Pharmaceuticals

20 stories about Pharmaceuticals
הפגנה מפגינים פיטורים טבע אשדוד

With No Buyers, Teva to Close Israeli Medical Equipment Plant

09.04.18|Dror Reich
The facility in Ashdod is one of five Teva intends to sell or close in its home country
יו"ר ועד עובדי טבע כפר סבא אלירן קוזליק

In Protest of New Bonus Plan, Teva Sued by Israeli Employees

15.03.18|Dror Reich
After announcing the cancellation of its annual bonuses for 2017 due to debt, the Israel-based drugmaker rolled out a performance-based bonus scheme for 2018 in February
מנכ"ל טבע החדש קור שולץ 2

Teva Increases Junk Senior Note Offering to $4.5 Billion

08.03.18|Lilach Baumer
Last week the debt-laden drugmaker announced a $3.5 billion-equivalent offering to repay its short-term $1.5 billion outstanding debt due July
תרופות טבע גלולות תרופה

Teva to Repay Due Loans with Junk Bond Private Offering

01.03.18|Lilach Baumer
The debt-laden generic drugmaker is offering around $3.5 billion in senior notes in both dollar and euro denominations
מנכ"ל טבע החדש קור שולץ 2

Teva Shut Down New York, Washington Offices, Says CEO

23.02.18|Dror Reich
In a meeting with investors in Israel, CEO Kåre Schultz said the Washington offices were used mainly by lobbyists, for which Teva has no further need
אורי טל טנא פרשן שוק ההון

Teva No Longer Provides Timeline for Recovery

21.02.18|Uri Tal-Tenne
In 2017, the company said it expected moderate growth in operating profits in the U.S. in 2020
מנכ"ל טבע החדש קור שולץ

Teva Turns to Meritocracy as Part of Turnaround Plan

18.02.18|Dror Reich
A new policy the company is rolling out would see Teva employees compensated according to key performance indicators
וורן באפט 2017 ברקשייר האתוויי

Berkshire Hathaway Takes Position in Generic Drugmaker Teva

15.02.18|Lilach Baumer
The holding company disclosed a $358 million stake in the struggling company
מטה טבע פתח תקווה

Teva Gets Fresh Cash, Fresh Woes

04.02.18|Dror Reich
After the troubled drugmaker finalized two deals that will enable it to repay some of its debt, S&P placed it on CreditWatch negative on Friday
מנכ"ל טבע החדש קור שולץ 2

As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites

10.01.18|Lilach Baumer
The drugmaker will shut down 20-25 manufacturing sites in the next two years, CEO Kåre Schultz said Monday
מנכ"ל טבע החדש קור שולץ 2

As U.S. Domestic Issuer, Teva Reveals Top Stock Owners

03.01.18|Dror Reich
Kåre Schultz, the newly-appointed CEO of generic drugmaker Teva Pharmaceutical Industries Ltd., is one of Teva's largest shareholders, a Wednesday filing to the U.S. Securities and Exchange Commission revealed
שם: מעבדה ביוטק וושי אפטק Lab Biotech WuXi AppTec

Merck, China’s WuXi AppTec to Launch Biotech Incubator in Israel

25.12.17|Meir Orbach
Israel-born businessman Mori Arkin and life sciences-focused venture capital fund Pontifax are also partners in the venture, set to launch in 2018
default image

Following Restructuring Announcements, Teva Reinstated as Israel’s Biggest Company

18.12.17|Lilach Baumer
Teva's stock jumped 18.7% on the New York Stock Exchange between Thursday market opening and Friday market close. Israeli Prime Minister Benjamin Netanyahu is expected to meet with CEO Kåre Schultz Tuesday
אחרי ה שביתה נתב"ג טבע פיטורים טיסות טרמינל

Tel Aviv Airport, Stock Market Open as Solidarity Strike Ends

17.12.17|Lior Gutman, Omri Milman and Micky Grunfeld
Israel’s largest labor union called for a half-day strike on Thursday, in support of Teva employees
פסקל סוריו מנכ"ל AstraZeneca

Once Future CEO Could have Taken Teva on a Different Path

14.12.17|Lilach Baumer, Golan Hazani, and Orr Hirschauge
AstraZeneca CEO Pascal Soriot, which backed out of Teva’s CEO position in July, planned on taking the company towards innovation instead of generic focus
מנכ"ל טבע החדש קור שולץ 2

Teva to Cut Around Half of Israeli Workforce, Outsource Operations

13.12.17|Dror Reich
An internal document reviewed by Calcalist reveals the troubled drugmaker's detailed domestic cost-cutting plans
מפעל טבע טק ב רמת חובב

Teva to Cut Jobs, Shut Down Some Israeli Operations

13.12.17|Dror Reich and Sefi Krupsky
On Thursday, the troubled drugmaker is expected to unveil its cutback plan. At its center is extensive layoffs and the reorganization and divestment of non-core assets
יצחק פטרבורג

Former Chairman Yitzhak Peterburg Leaves Teva

13.12.17|Lilach Baumer
Mr. Peterburg was the troubled drugmaker's interim CEO between February and November 1, when Kåre Schultz took helm
מנכ"ל טבע החדש קור שולץ 1

Teva to Unveil Strategic Plan, Layoffs Thursday

12.12.17|Dror Reich
Last month the debt-riddled drug maker announced a rehabilitation plan amidst rumors of upcoming employee cuts
מייסד קייט פארמה אריה בלדגרין

Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company

10.12.17|Lilach Baumer
California-based Cell Design Labs will be acquired in a deal valued at up to $567 million
Previous ArticlesMore Articles